Table 1.
Characteristics of the patients at baseline
| Characteristics | All patients | Well respondersa | Poor responders | |
|---|---|---|---|---|
| (n = 25) | (n = 11) | (n = 14) | ||
| Age at enrollment (years) | ||||
| Mean ± s.d. | 65.2 ± 5.3 | 65.0 ± 6.1 | 65.3 ± 4.6 | |
| Median (range) | 65 (55, 75) | 65 (55, 75) | 65 (57, 72) | |
| Sex (n,%) | ||||
| Female | 3 (12) | 2 (18) | 1 (7) | |
| Male | 22 (88) | 9 (82) | 13 (93) | |
| Tumor location (n, %) | ||||
| Proximal third | 3 (12) | 2 (18) | 1 (7) | |
| Middle third | 11 (44) | 5 (46) | 6 (43) | |
| Distal third | 11(44) | 4 (36) | 7 (50) | |
| Clinical disease stageb (n, %) | ||||
| II | 3 (12) | 2 (18) | 1 (7) | |
| III | 20 (80) | 8 (73) | 12 (86) | |
| IV | 2 (8) | 1 (9) | 1 (7) | |
| Tumor length (x ± s, mm) | 40.5 ± 12.7 | 40.3 ± 12.8 | 40.6 ± 13.1 | |
| Tumor diameter (x ± s, mm) | 15.3 ± 4.1 | 15.3 ± 4.3 | 15.3 ± 4.2 | |
| Smoking status (n, %) | ||||
| Former/current | 10 (40) | 6 (55) | 4 (29) | |
| Never | 15 (60) | 5 (45) | 10 (71) | |
| PD-L1 statusc (n, %) | ||||
| CPS > 10 | 4 (16) | 3 (27) | 1 (7) | |
| CPS < 10 | 18 (72) | 7 (64) | 11 (79) | |
| unknown | 3 (12) | 1 (9) | 2 (14) | |
a Well responders were defined as having 33% or fewer residual viable tumor cells in the resected tumor. Poor responders were defined as having 33% or more residual viable tumor cells in the resected tumor.
b The clinical disease stage was evaluated according to criteria in the AJCC, eighth edition.
c PD-L1 status was evaluated by CPS using Dako 22C3 antibody.